Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study
2011

Effectiveness of Pandemic Influenza Vaccine in Europe (2009-2010)

Sample size: 2902 publication 10 minutes Evidence: high

Author Information

Author(s): Marta Valenciano, Esther Kissling, Jean-Marie Cohen, Beatrix Oroszi, Anne-Sophie Barret, Caterina Rizzo, Baltazar Nunes, Daniela Pitigoi, Amparro Larrauri Cámara, Anne Mosnier, Judith K. Horvath, Joan O'Donnell, Antonino Bella, Raquel Guiomar, Emilia Lupulescu, Camelia Savulescu, Bruno C. Ciancio, Piotr Kramarz, Alain Moren

Primary Institution: EpiConcept, Paris, France

Hypothesis

What is the effectiveness of the 2009-2010 pandemic influenza vaccine against H1N1 in Europe?

Conclusion

The pandemic monovalent vaccine provided good protection against H1N1, while the seasonal influenza vaccine had no effect.

Supporting Evidence

  • The pandemic vaccine was effective in preventing H1N1 illness in patients who sought medical help.
  • Good vaccine effectiveness was observed as early as 8 days after vaccination.
  • The study included data from seven European countries.
  • Adjusted vaccine effectiveness estimates were calculated using logistic regression.
  • Low incidence of medically attended H1N1 illness limited the statistical power of the study.
  • Individuals were considered vaccinated if they received the vaccine more than 14 days before symptom onset.
  • Results suggest that the pandemic vaccine was more effective in younger individuals and those without chronic diseases.
  • The seasonal influenza vaccine showed no protective effect against H1N1.

Takeaway

The study found that the pandemic flu vaccine worked well to protect people from getting sick, but the regular flu shot didn't help at all.

Methodology

A multicentre case-control study using sentinel practitioner surveillance networks from seven European countries.

Potential Biases

Potential biases due to the test-negative design, confounding factors, and missing values.

Limitations

The late availability of the pandemic vaccine and limited coverage hampered the ability to study vaccine benefits during the outbreak.

Participant Demographics

Patients from seven European countries, with a median age of 12 years for cases and 27 years for controls.

Statistical Information

P-Value

0.001

Confidence Interval

95% CI 45.6–85.5

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pmed.1000388

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication